MiNK Therapeutics' expenses in Q4 2024 were not disclosed in the available financial reports. However, the company's financial statements for Q3 2024 provide insights into its financial trends and challenges12.
- Cash Flow and Financial Position:
- MiNK Therapeutics reported a cash balance of $6.3 million at the end of Q3 202412.
- The company used $3 million in operations over the three months ending September 2024 and $7.8 million over the nine months ending September 202423.
- This cash usage indicates ongoing financial strain, which could affect expenses in Q4 2024 if no additional funding was secured.
- Financial Performance:
- MiNK Therapeutics had a net loss of $1.8 million, or 5¢ per share, for the three months ending September 20242.
- The net loss was reduced from $5.1 million, or 15¢ per share, over the same period in 2023, indicating improved operational efficiency2.
- However, the net loss for the nine months ending September 2024 was $8.3 million, or 22¢ per share2, which suggests that Q4 2024 expenses could be significant if the company continued to operate at a loss.
- Comparison with Previous Quarters:
- MiNK Therapeutics’ cash balance at the end of Q3 2024 was lower than the $7.8 million used in operations over the nine months ending September 202423.
- This implies that the company may have relied on existing cash reserves or additional funding during Q4 2024 to meet its expenses, especially given the absence of disclosed expenses for this quarter.
In conclusion, while specific Q4 2024 expenses are not available, it is clear that MiNK Therapeutics continued to operate at a net loss in Q3 2024, which could be an indicator of significant expenses in Q4 2024. The company's reliance on cash reserves and potential additional funding may have helped mitigate these expenses, but the overall financial position remains challenging.
5/8/2025 08:42am
